07:00 , May 12, 2016 |  BC Innovations  |  Targets & Mechanisms

Another shot at the flu

While most efforts to suppress flu focus on boosting the immune system through vaccination, a group at Yale University has found evidence showing it is the inflammatory response to infection, not the infection itself, that...
08:00 , Jan 11, 2016 |  BC Week In Review  |  Clinical News

AC-201 CR: Interim Phase IIa data

Interim data from 36 gout patients in the first cohort of the double-blind, Taiwanese Phase IIa AC-201-GOU-002 trial showed that twice-daily oral AC-201 CR met the criteria of >=2 more responders, defined as achieving a...
08:00 , Jan 5, 2015 |  BC Week In Review  |  Clinical News

AC-201: Phase II started

TWi began a double-blind, international Phase II trial to compare 100 mg oral AC-201 twice daily for 12 weeks plus febuxostat vs. placebo plus febuxostat in about 140 patients. TWi Pharmaceuticals Holding Inc. (GreTai:4180), Taipei,...
01:55 , Dec 5, 2013 |  BC Extra  |  Financial News

TWi raises $111.5 million in Taiwanese IPO

TWi Pharmaceuticals Holding Inc. (GreTai:4180) raised NT$3.3 billion ($111.5 million) through the sale of 13.3 million shares at NT$248 in an IPO in Taiwan -- the largest IPO for a pharma or biotech in the...
01:17 , Dec 4, 2013 |  BC Extra  |  Financial News

TWi up in trading debut in Taiwan

TWi Pharmaceuticals Holding Inc. (GreTai:4180) was up NT$82 to NT$330 in its first day of trading on Tuesday on the GreTai Securities Market. The company, which could not be reached for details, had said when...
23:13 , Jul 3, 2013 |  BC Extra  |  Financial News

TWi seeking formal listing on GreTai

TWi Pharmaceuticals Holding Inc. (GreTai-E:4180) applied for a formal listing on the GreTai Securities Market. The company said it plans to raise $60-$80 million towards the end of the year in an IPO on the...
01:34 , Nov 1, 2012 |  BC Extra  |  Financial News

TWi Pharmaceuticals seeks Taiwanese listing

TWi Pharmaceuticals Holding Inc. (Taipei, Taiwan) began the formal process to list on the GreTai Securities Market in Taiwan by applying as an over-the-counter emerging stock on the exchange. To obtain a formal listing on...
07:00 , Aug 13, 2012 |  BC Week In Review  |  Clinical News

AC-201: Phase IIb data

Data from 259 Type II diabetics inadequately controlled on up to 3 anti-diabetic drugs in the intent-to-treat (ITT) population of a double-blind, U.S. and Taiwanese Phase IIb trial showed that twice-daily 75 mg oral AC-201...
01:10 , Aug 7, 2012 |  BC Extra  |  Clinical News

TWi Pharma reports data for AC-201 in Type II diabetes

TWi Pharmaceuticals Holding Inc. (Taipei, Taiwan) said twice-daily 75 mg oral AC-201 led to a significant placebo-corrected reduction in HbA1c from baseline to week 24, the primary endpoint, of 0.35% (p<0.05) in a Phase IIb...
07:00 , Sep 12, 2011 |  BC Week In Review  |  Clinical News

AC-201: Completed Phase IIb enrollment

TWi completed enrollment of 240 patients with Type II diabetes in a double-blind, placebo-controlled, U.S. and Taiwanese Phase IIb trial evaluating 25, 50 and 75 mg twice-daily AC-201 for 24 weeks. TWi spun out of...